{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:17:33Z","timestamp":1790399853157,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004442","name":"National Science Centre","doi-asserted-by":"crossref","award":["DEC-2012\/05\/B\/NZ7\/02705"],"award-info":[{"award-number":["DEC-2012\/05\/B\/NZ7\/02705"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.pharep.2014.11.003","type":"journal-article","created":{"date-parts":[[2014,11,22]],"date-time":"2014-11-22T01:09:08Z","timestamp":1416618548000},"page":"465-472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression"],"prefix":"10.1007","volume":"67","author":[{"given":"Kinga","family":"Sa\u0142at","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Podkowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kulig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dziubina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Filipek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Librowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2014.11.003_bib0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pbb.2013.06.013","article-title":"Evaluation of anxiolytic-like, anticonvulsant, antidepressant-like and antinociceptive properties of new 2-substituted 4-hydroxybutanamides with affinity for GABA transporters in mice","volume":"110","author":"Sa\u0142at","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharep.2014.11.003_bib0010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejmech.2013.04.063","article-title":"Synthesis of N-substituted acyclic \u03b2-amino acids and their investigation as GABA reuptake inhibitors","volume":"65","author":"Sitka","year":"2013","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.pharep.2014.11.003_bib0015","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1734-1140(12)70877-0","article-title":"Synthesis and pharmacological properties of new GABA uptake inhibitors","volume":"64","author":"Sa\u0142at","year":"2012","journal-title":"Pharmacol Rep"},{"issue":"12","key":"10.1016\/j.pharep.2014.11.003_bib0020","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.2174\/138955708786141025","article-title":"Multi-faceted aspects of gamma-hydroxybutyric acid: a neurotransmitter, therapeutic agent and drug of abuse","volume":"8","author":"Castelli","year":"2008","journal-title":"Mini Rev Med Chem"},{"issue":"11","key":"10.1016\/j.pharep.2014.11.003_bib0025","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.bmc.2013.02.056","article-title":"Synthesis and evaluation of N-substituted nipecotic acid derivatives with an unsymmetrical bis-aromatic residue attached to a vinyl ether spacer as potential GABA uptake inhibitors","volume":"21","author":"Quandt","year":"2013","journal-title":"Bioorg Med Chem"},{"issue":"17","key":"10.1016\/j.pharep.2014.11.003_bib0030","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1016\/j.bmc.2013.06.038","article-title":"2-Substituted 4-hydroxybutanamides as potential inhibitors of c-aminobutyric acid transporters mGAT1\u2013mGAT4: synthesis and biological evaluation","volume":"21","author":"Kowalczyk","year":"2013","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"10.1016\/j.pharep.2014.11.003_bib0035","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881109103091","article-title":"Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL\/6 mice","volume":"24","author":"Thoeringer","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.pharep.2014.11.003_bib0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4155\/fmc.10.285","article-title":"An historical perspective on GABAergic drugs","volume":"3","author":"Froestl","year":"2011","journal-title":"Future Med Chem"},{"issue":"4","key":"10.1016\/j.pharep.2014.11.003_bib0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.ajp.0000110637.14355.77","article-title":"Tiagabine and gabapentin for the management of chronic pain","volume":"21","author":"Todorov","year":"2005","journal-title":"Clin J Pain"},{"issue":"6\u20137","key":"10.1016\/j.pharep.2014.11.003_bib0050","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neuint.2005.12.031","article-title":"A novel selective gamma-aminobutyric acid transport inhibitor demonstrates a functional role for GABA transporter subtype GAT2\/BGT-1 in the CNS","volume":"48","author":"Clausen","year":"2006","journal-title":"Neurochem Int"},{"issue":"10","key":"10.1016\/j.pharep.2014.11.003_bib0055","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2174\/0929867003374363","article-title":"The GABA transporter and its inhibitors","volume":"7","author":"Soudijn","year":"2000","journal-title":"Curr Med Chem"},{"issue":"6","key":"10.1016\/j.pharep.2014.11.003_bib0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/1568007043336716","article-title":"GABA puts a stop to pain","volume":"3","author":"Jasmin","year":"2004","journal-title":"Curr Drugs Targets CNS Neurol Disord"},{"key":"10.1016\/j.pharep.2014.11.003_bib0065","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejmech.2014.06.024","article-title":"Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides","volume":"83","author":"Kowalczyk","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.pharep.2014.11.003_bib0070","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.pbb.2014.05.021","article-title":"Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures","volume":"124","author":"Dos","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.pharep.2014.11.003_bib0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharep.2014.11.003_bib0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0022-3565(25)05180-8","article-title":"Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines","volume":"107","author":"Eddy","year":"1953","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharep.2014.11.003_bib0085","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1124\/jpet.302.3.1168","article-title":"Comparison of antiepileptic drugs tiagabine, lamotrigine and gabapentin in mouse models of acute, prolonged and chronic nociception","volume":"302","author":"Laughlin","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharep.2014.11.003_bib0090","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/BF00177912","article-title":"The use of a plus-maze to measure anxiety in the mouse","volume":"92","author":"Lister","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharep.2014.11.003_bib0095","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0028-3908(71)90074-8","article-title":"Evaluation of a rapid technique for detecting minor tranquilizers","volume":"10","author":"Aron","year":"1971","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2014.11.003_bib0100","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"3","key":"10.1016\/j.pharep.2014.11.003_bib0105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1734-1140(09)70087-8","article-title":"Synergistic interaction of gabapentin with tiagabine in the hot-plate test in mice: an isobolographic analysis","volume":"61","author":"\u0141uszczki","year":"2009","journal-title":"Pharmacol Rep"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2014.11.003_bib0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejphar.2003.08.063","article-title":"Inhibition of \u03b3-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures","volume":"479","author":"Dalby","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharep.2014.11.003_bib0115","series-title":"Handbook of neurochemistry and molecular neurobiology. Neural membranes and transport","article-title":"Functional and pharmacological aspects of GABA transporters","author":"Madsen","year":"2007"},{"issue":"4","key":"10.1016\/j.pharep.2014.11.003_bib0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2174\/1568007033482788","article-title":"GABA transporters and GABA-transaminase as drug targets","volume":"2","author":"Sarup","year":"2003","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2014.11.003_bib0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2008.12.046","article-title":"Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis","volume":"605","author":"Dudra-Jastrzebska","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2014.11.003_bib0130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0014-2999(91)90438-V","article-title":"Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor","volume":"196","author":"Nielsen","year":"1991","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharep.2014.11.003_bib0135","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.nbd.2011.08.013","article-title":"Strain differences in seizure-induced cell death following pilocarpine-induced status epilepticus","volume":"45","author":"Schauwecker","year":"2012","journal-title":"Neurobiol Dis"},{"issue":"2\u20134","key":"10.1016\/j.pharep.2014.11.003_bib0140","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jneumeth.2008.04.019","article-title":"The pilocarpine model of temporal lobe epilepsy","volume":"172","author":"Curia","year":"2008","journal-title":"J Neurosci Methods"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2014.11.003_bib0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.eplepsyres.2005.07.006","article-title":"Functional GABA uptake at inhibitory synapses in CA1 of chronically epileptic rats","volume":"66","author":"Stief","year":"2005","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.pharep.2014.11.003_bib0150","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1734-1140(09)70137-9","article-title":"Effect of caffeine on the anticonvulsant effects of oxcarbazepine, lamotrigine and tiagabine in a mouse model of generalized tonic\u2013clonic seizures","volume":"61","author":"Chro\u015bci\u0144ska-Krawczyk","year":"2009","journal-title":"Pharmacol Rep"},{"issue":"2\u20133","key":"10.1016\/j.pharep.2014.11.003_bib0155","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eplepsyres.2011.09.002","article-title":"Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis","volume":"98","author":"\u0141uszczki","year":"2012","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.pharep.2014.11.003_bib0160","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0091-3057(03)00081-9","article-title":"Interactions of tiagabine with some antiepileptics in the maximal electroshock in mice","volume":"75","author":"\u0141uszczki","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"issue":"10","key":"10.1016\/j.pharep.2014.11.003_bib0165","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/sj.npp.1300243","article-title":"Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice","volume":"28","author":"\u0141uszczki","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.pharep.2014.11.003_bib0170","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1523\/JNEUROSCI.3364-04.2005","article-title":"GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum","volume":"25","author":"Chiu","year":"2005","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharep.2014.11.003_bib0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-1211(97)00033-8","article-title":"Anticonvulsant properties of two GABA uptake inhibitors NNC 05-2045 and NNC 05-2090, not acting preferentially on GAT-1","volume":"28","author":"Dalby","year":"1997","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.pharep.2014.11.003_bib0180","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nurt.2006.11.010","article-title":"Molecular targets for antiepileptic drug development","volume":"4","author":"Meldrum","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.pharep.2014.11.003_bib0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1568026053386962","article-title":"Mechanisms of action of antiepileptic drugs","volume":"5","author":"Czapi\u0144ski","year":"2005","journal-title":"Curr Top Med Chem"},{"issue":"8","key":"10.1016\/j.pharep.2014.11.003_bib0190","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.neuropharm.2007.09.008","article-title":"GABA transporter type 1 (GAT-1) uptake inhibition reduces stimulated aspartate and glutamate release in the dorsal spinal cord in vivo via different GABAergic mechanisms","volume":"53","author":"Smith","year":"2007","journal-title":"Neuropharmacology"},{"issue":"2\u20133","key":"10.1016\/j.pharep.2014.11.003_bib0195","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0014-2999(99)00034-5","article-title":"Tiagabine antinociception in rodents depends on GABA receptor B activation: parallel antinociception testing and medial thalamus GABA microdialysis","volume":"368","author":"Ipponi","year":"1999","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharep.2014.11.003_bib0200","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.pnpbp.2006.11.020","article-title":"Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy","volume":"31","author":"\u0141uszczki","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.pharep.2014.11.003_bib0205","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/jpet.102.036251","article-title":"Inhibition of improgan antinociception by the cannabinoid CB1 antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB1 receptors","volume":"303","author":"Hough","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharep.2014.11.003_bib0210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/157015906778019527","article-title":"Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes","volume":"4","author":"Manzanares","year":"2006","journal-title":"Curr Neuropharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharep.2014.11.003_bib0215","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sj.bjp.0706443","article-title":"GABA and glycine as neurotransmitters: a brief history","volume":"147","author":"Bowery","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2014.11.003_bib0220","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jnr.10677","article-title":"Hyperalgesic effects of gamma-aminobutyric acid transporter I in mice","volume":"73","author":"Hu","year":"2003","journal-title":"J Neurosci Res"},{"issue":"2","key":"10.1016\/j.pharep.2014.11.003_bib0225","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/jnr.21499","article-title":"Hypoalgesia in mice lacking GABA transporter subtype 1","volume":"86","author":"Xu","year":"2008","journal-title":"J Neurosci Res"},{"issue":"7","key":"10.1016\/j.pharep.2014.11.003_bib0230","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.neuropharm.2005.01.013","article-title":"Comparison of the effects of anticonvulsant drugs with diverse mechanisms of action in the formalin test in rats","volume":"48","author":"Shannon","year":"2005","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharep.2014.11.003_bib0235","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.pharmthera.2009.11.007","article-title":"Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs","volume":"125","author":"Madsen","year":"2010","journal-title":"Pharmacol Ther"},{"issue":"5\u20136","key":"10.1016\/j.pharep.2014.11.003_bib0240","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s007020200071","article-title":"Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats","volume":"109","author":"Schmitt","year":"2002","journal-title":"J Neural Transm"},{"issue":"1","key":"10.1016\/j.pharep.2014.11.003_bib0245","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuropharm.2011.08.040","article-title":"The GABA system in anxiety and depression and its therapeutic potential","volume":"62","author":"Mohler","year":"2012","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2014.11.003_bib0250","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00008877-199903000-00002","article-title":"Effects of GABA-transporter (GAT) inhibitors on rat behavior in open-field and elevated plus-maze","volume":"10","author":"Schmitt","year":"1999","journal-title":"Behav Pharmacol"},{"issue":"7","key":"10.1016\/j.pharep.2014.11.003_bib0255","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/sj.npp.1301281","article-title":"Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1","volume":"32","author":"Liu","year":"2007","journal-title":"Neuropsychopharmacology"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014003375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014003375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:49Z","timestamp":1752611749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2014.11.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1734114014003375"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2014.11.003","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2014.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Urban & Partner Sp. z o.o.","name":"copyright","label":"Copyright"}]}}